KOREA FUEL-TECH CORPORATION
Korea Fuel-Tech makes carbon canisters, plastic filler necks, and trim parts for automakers including Hyundai, Kia, GM, and Chinese OEMs.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureKorea Fuel-Tech Corporation was founded in 2010 and listed on KOSDAQ the same year as an automotive parts manufacturer. Its core products include carbon canisters that absorb fuel tank evaporative gas onto activated carbon and return it to the engine, plastic filler necks that safely convey fuel to the tank, and interior/exterior trim parts including sunshades. In 2025, sales reached KRW 366.4 billion for carbon canisters, KRW 119.1 billion for plastic filler necks, and KRW 307.4 billion for trim parts, with customers diversified across five domestic automakers including Hyundai and Kia, as well as GM, Renault, Volkswagen, Skoda, Volvo, Nissan, Porsche, and Chinese local OEMs (LYNK&CO, Li Auto, HOZON).
Products & technology
- Carbon CanisterAbsorbs fuel tank evaporative gas onto activated carbon and returns it to the engine for combustion
- Plastic Filler NeckFuel conduit that safely conveys fuel to the fuel tank
- Trim Parts (incl. Sunshade)Components including sunshades that reduce driver fatigue and form vehicle interior/exterior trim
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition